Robert Wise, MD

Robert Wise is a professor of Medicine and Instructor of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. He also holds a joint appointment in Environmental Health Sciences and Epidemiology at the Johns Hopkins Bloomberg School of Public Health. His areas of clinical expertise include chronic obstructive pulmonary disease, critical care medicine and pulmonary disease. Dr. Wise serves as Director of Research for the Division of Pulmonary and Critical Care Medicine at Johns Hopkins. Dr. Wise earned his M.D. from Harvard Medical School. He completed his residency at the University of Michigan Health System. He performed fellowships in respiratory therapy and environmental health sciences at Johns Hopkins. His research focuses on chronic obstructive lung diseases. He is a worldwide expert in the design and conduct of clinical trials focused on asthma and COPD, and the principal investigator of the NHLBI T32 multidisciplinary training grant in the Division of Pulmonary and Critical Care at JHU.  Dr. Wise has over 216 publications and has mentored over 25 pulmonary and critical care fellows at JHU and >80% have successful academic careers. 

SELECTED PUBLICATIONS

  1. Wise RA, Connett JE, Weinmann GG, Scanlon PD, Skeans MA and the Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909
  2. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE and National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-2073
  3. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P and the TIOSPIR Investigators. Tiotropium Respimat Inhaler and the Risk of Death in COPD. N Engl J Med 2013; 369(16):1491-501
  4. Wise RA (Corresponding Author) for the Long-Term Oxygen Treatment Trial Research Group. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016;375:1617-1627
  5. Castro M, Dozor AJ, Fish JE, Irvin CG, Scharf SM, Scheipeter ME, Holbrook JT, Tonascia J, Wise RA. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001; 345:1529-1536
  6. Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, Wise RA for the American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356:2027-2039
  7. Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360:1487-1499 PMCID: PMC2974569
  8. Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima JJ, Mastronarde JG, Sockrider MM, Teague WG. (for the ALA-ACRC) Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA. 2012;307(4):373-81. PMCID: PMC4153372
  9. Wise RA, Connett J, Kurnow K, Grill J, Johnson L, Kanner R and Enright P. Selection of spirometric measurements in a clinical trial, the Lung Health Study. Am J Respir Crit Care Med 1995; 151:675-681
  10. Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA and National Emphysema Treatment Trial Research Group. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 2003; 167:1522-1527
  11. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62:411-415
  12. Nguyen JM, Holbrook JT, Wei CY, Gerald LB, Teague WG, Wise RA; American Lung Association Asthma Clinical Research Centers. Validation and psychometric properties of the Asthma Control Questionnaire among children. J Allergy Clin Immunol.  2014;133:91-7 PMCID: PMC3874246
  13. White B, Moore WC, Wigley FM, Xiao HQ and Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947-954
  14. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M and Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666